ArticleJournal of extracellular biology2026
Workflow for the Isolation and Characterisation of Human Milk Extracellular Vesicles (HMEVs) and Their Inflammatory Biomarker Profile.
Article in Journal of extracellular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Workflow for the Isolation and Characterisation of Human Milk Extracellular Vesicles (HMEVs) and Their Inflammatory Biomarker Profile.Journal of extracellular biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human milk extracellular vesicles (HMEVs), secreted by mammary epithelial cells, are enriched in bioactive molecules that support intestinal epithelial integrity. Among these, oxylipins, that is, lipid mediators derived from polyunsaturated fatty acids, are gaining interest for their immunomodulatory and neuroprotective functions in breastfed infants. However, current workflows for oxylipin profiling in HMEVs often lack sensitivity or breadth, limiting mechanistic insights. This study presents an optimised workflow for comprehensive oxylipin profiling in HMEVs. HMEVs were isolated via size-exclusion chromatography and ultracentrifugation, followed by characterisation using attenuated total reflectance-Fourier transform infrared spectroscopy, Western blotting, Exoview immunocapture, tunable resistive pulse sensing and transmission electron microscopy. The influence of different pre-analytical protocols on HMEV recovery was assessed. Cryolysis with liquid nitrogen was employed for vesicle lysis before targeted oxylipin quantification using ultra-performance liquid chromatography-tandem mass spectrometry. The analysis of 10 human milk samples revealed 9,10-DiHOME, 12,13-DiHOME and 11,12-EET as the most abundant oxylipins, with concentrations ranging from 0.5 to 3.7, 0.8 to 4.5 and 0.1 to 0.3 nM, respectively. This refined pipeline enables in-depth oxylipin profiling in HMEVs and serves as a robust platform for future in vitro and in vivo investigations into EV-mediated lipid signalling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.